High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL

被引:174
作者
Derby, MA [1 ]
Alexander-Miller, MA [1 ]
Tse, R [1 ]
Berzofsky, JA [1 ]
机构
[1] NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.4049/jimmunol.166.3.1690
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Previously, we observed that high-avidity CTL are much more effective in vivo than low-avidity CTL in elimination of infected cells, but the mechanisms behind their superior activity remained unclear. In this study, we identify two complementary mechanisms: 1) high-avidity CTL lyse infected cells earlier in the course of a viral infection by recognizing lower Ag densities than those distinguished by low-avidity CTL and 2) they initiate lysis of target cells more rapidly at any given Ag density. Alternative mechanisms were excluded, including: 1) the possibility that low-avidity CTL might control virus given more time (virus levels remained as high at 6 days following transfer as at 3 days) and 2) that differences in efficacy might be correlated with homing ability. Furthermore, adoptive transfer of high- and low-avidity CTL into SCID mice demonstrated that transfer of a 10-fold greater amount of low-avidity CTC could only partially compensate for their decreased ability to eliminate infected cells. Thus, we conclude that high-avidity CTL exploit two complementary mechanisms that combine to prevent the spread of virus within the animal: earlier recognition of infected cells when little viral protein has been made and more rapid lysis of infected cells.
引用
收藏
页码:1690 / 1697
页数:8
相关论文
共 45 条
  • [31] Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positiye relapsed Hodgkin's disease
    Roskrow, MA
    Suzuki, N
    Gan, YJ
    Sixbey, JW
    Ng, CYC
    Kimbrough, S
    Hudson, M
    Brenner, MK
    Heslop, HE
    Rooney, CM
    [J]. BLOOD, 1998, 91 (08) : 2925 - 2934
  • [32] Santin AD, 2000, EUR J GYNAECOL ONCOL, V21, P17
  • [33] IN-VITRO PREDICTORS OF THERAPEUTIC RESPONSE IN MELANOMA PATIENTS RECEIVING TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2
    SCHWARTZENTRUBER, DJ
    HOM, SS
    DADMARZ, R
    WHITE, DE
    YANNELLI, JR
    STEINBERG, SM
    ROSENBERG, SA
    TOPALIAN, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) : 1475 - 1483
  • [34] Soda H, 1999, J SURG ONCOL, V72, P211, DOI 10.1002/(SICI)1096-9098(199912)72:4<211::AID-JSO6>3.0.CO
  • [35] 2-A
  • [36] AN IMMUNODOMINANT EPITOPE OF THE HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN GP160 RECOGNIZED BY CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE-RESTRICTED MURINE CYTO-TOXIC LYMPHOCYTES-T
    TAKAHASHI, H
    COHEN, J
    HOSMALIN, A
    CEASE, KB
    HOUGHTEN, R
    CORNETTE, JL
    DELISI, C
    MOSS, B
    GERMAIN, RN
    BERZOFSKY, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (09) : 3105 - 3109
  • [37] TAKESHITA T, 1995, J IMMUNOL, V154, P1973
  • [38] Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome
    Tan, RS
    Xu, XN
    Ogg, GS
    Hansasuta, P
    Dong, T
    Rostron, T
    Luzzi, G
    Conlon, CP
    Screaton, GR
    McMichael, AJ
    Rowland-Jones, S
    [J]. BLOOD, 1999, 93 (05) : 1506 - 1510
  • [39] Serial triggering of TCRs: A basis for the sensitivity and specificity of antigen recognition
    Valitutti, S
    Lanzavecchia, A
    [J]. IMMUNOLOGY TODAY, 1997, 18 (06): : 299 - 304
  • [40] SERIAL TRIGGERING OF MANY T-CELL RECEPTORS BY A FEW PEPTIDE-MHC COMPLEXES
    VALITUTTI, S
    MULLER, S
    CELLA, M
    PADOVAN, E
    LANZAVECCHIA, A
    [J]. NATURE, 1995, 375 (6527) : 148 - 151